Monday, 26 October 2009
Friday, 23 October 2009
Thursday, 22 October 2009
Mike Lucas on Low Dose Naltrexone
Michael Moore's colleague Mike Lucas weighs on the Low Dose Naltrexone issue -
Why won’t the drug companies shell out cash for a promising drug that requires FDA approval?
Why won’t the drug companies shell out cash for a promising drug that requires FDA approval?
Subscribe to:
Posts (Atom)
Posts
